LENVIMA 4 mg hard capsules
APHP220267
Phase 2 small_molecule active
Quick answer
LENVIMA 4 mg hard capsules for Non-resectable hepatocellular carcinoma (HCC) is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Non-resectable hepatocellular carcinoma (HCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active